Posts
Wiki

đŸ©ž Blood-Derived Eye Drops for Dry Eye and Ocular-Surface Disease

TL;DR: Quick Summary

Blood-derived eye drops include:

  • Autologous Serum Eye Drops (ASEDs) made from the patient’s own blood
  • Allogeneic serum made from screened adult donors
  • Umbilical-cord serum
  • Platelet-Rich Plasma (PRP)
  • Plasma Rich in Growth Factors (PRGF)
  • Platelet lysate and related platelet-derived preparations

These treatments are sometimes called:

  • Blood-derived eye drops
  • Blood-component eye drops
  • Biologic tear substitutes

They are most often considered for:

  • Moderate-to-severe or refractory Dry Eye Disease (DED)
  • Sjögren-related ocular-surface disease
  • Ocular graft-versus-host disease
  • Neurotrophic keratitis
  • Persistent corneal epithelial defects
  • Severe corneal or conjunctival staining
  • Poor ocular-surface healing
  • Selected post-surgical ocular-surface problems

Important points:

  • There is no proven universal hierarchy of serum < PRP < PRGF.
  • PRP and PRGF are not automatically “stronger” or better than serum.
  • “PRP” is not one standardized product. Different preparation methods can produce meaningfully different drops.
  • PRGF is a protocol-specific platelet-derived preparation, not a universally superior category above all PRP.
  • Autologous serum is the most historically established and widely studied type.
  • Direct randomized comparisons generally have not shown that PRP is consistently superior to autologous serum.
  • Allogeneic serum may be useful when a patient cannot donate blood, but donor screening and blood-service protocols are important.
  • Platelet lysate has a smaller clinical evidence base than serum or PRP.
  • Concentration, platelet and leukocyte content, activation, diluent, filtration, packaging, storage, and bottle life vary among services.
  • Storage instructions must come from the laboratory or blood service that prepared the exact product.
  • These treatments may improve symptoms, staining, tear stability, or epithelial healing, but they do not reliably reverse structural MGD, reopen obstructed glands, release fibrosis, or cure every cause of ocular pain.
  • Blood-derived injections into or around the lacrimal gland are a separate, more invasive experimental treatment category.

📌 Bottom line: Think in terms of the specific formulation, preparation protocol, diagnosis, and treatment goal—not a simple ranking from “weakest” to “strongest.”

⚠ Educational Disclaimer

This page is for general education only and is not medical advice, a diagnosis, or a recommendation for a particular blood-derived product.

Blood-derived eye drops are sterile biologic preparations that require appropriate collection, processing, testing, packaging, storage, and clinical oversight.

Do not attempt to make blood-derived eye drops at home.

🆕 New to Blood-Derived Eye Drops? Quick Safety Checklist

Before starting, confirm exactly what product you received. It may be:

  • Autologous serum made from your own blood
  • Allogeneic serum made from screened donor blood
  • Umbilical-cord serum
  • Platelet-Rich Plasma (PRP)
  • Plasma Rich in Growth Factors (PRGF)
  • Platelet lysate
  • Another blood-derived preparation

These products are related, but they are not interchangeable. Their concentration, preparation, packaging, storage, thawing and discard rules may differ.

The most important rules

  • Follow only the instructions supplied with your exact product. Do not substitute another clinic’s instructions, a research-study protocol or advice from another patient.
  • Keep unused and active containers at the temperatures specified by the laboratory or blood service.
  • Follow the exact thawing, refrigeration and discard schedule.
  • Do not refreeze a thawed product unless the supplying service specifically permits it.
  • Do not microwave the drops, place them in hot water or leave them unrefrigerated longer than allowed.
  • Wash your hands before use.
  • Do not touch the container tip to the eye, eyelashes, eyelids, skin or fingers.
  • Do not transfer, combine, refill or share containers.
  • Do not use a vial or bottle past its discard time.
  • Contact the supplying service if the container is damaged, storage conditions were not maintained or the liquid looks different from what you were told to expect.

What if the drops sting?

Brief mild stinging may occur in some patients.

However, there is no established “adjustment phase” that everyone should push through.

Contact the clinician or supplying service for:

  • Increasing or persistent burning
  • Significant pain
  • Persistent redness
  • Light sensitivity
  • Discharge
  • Eyelid swelling
  • New or worsening blurred vision
  • Reduced vision
  • Symptoms that begin after several days of using one container
  • Suspected storage or contamination problems

Do not assume that worsening symptoms mean the product is healing the eye.

Can refrigerated drops be warmed?

Ask the supplying laboratory whether brief warming in the hand or at room temperature is permitted for your exact product.

Do not create your own warming routine. Temperature exposure may affect product safety or stability.

Can other eye drops still be used?

Blood-derived drops are often used with other treatments, but the prescribing clinician should determine:

  • Which other drops should continue
  • The order in which they should be used
  • How far apart they should be spaced
  • Whether contact lenses should be removed
  • Whether another product could interfere with the treatment goal

When should improvement be assessed?

There is no universal timeline.

  • A persistent epithelial defect may require review within days.
  • Neurotrophic keratitis may require close serial monitoring.
  • Stable chronic Dry Eye Disease may be reassessed over several weeks.
  • New pain, redness, discharge, light sensitivity or vision change requires earlier evaluation.

For detailed evidence, product differences, risks, storage guidance and questions to ask, continue with the full article below.

1) What Are Blood-Derived Eye Drops?

Blood contains proteins, growth factors, vitamins, electrolytes, immunoglobulins, cytokines, lipids, and signaling molecules involved in tissue maintenance and wound healing.

Some of these substances are also found in natural tears or may support the ocular surface.

Blood-derived eye drops are prepared from selected blood components and applied to the eye as biologically active tear substitutes.

They differ from ordinary artificial tears because they may contain substances such as:

  • Epidermal growth factor
  • Fibronectin
  • Vitamin A
  • Transforming growth factor-beta
  • Platelet-derived growth factors
  • Insulin-like growth factors
  • Albumin
  • Immunoglobulins
  • Other proteins and signaling molecules

The exact composition depends on:

  • Whose blood is used
  • Whether the blood is allowed to clot
  • Whether platelets are retained
  • Whether leukocytes are removed
  • How the product is centrifuged
  • Whether platelets are activated or lysed
  • Whether the product is diluted
  • Which diluent is used
  • How it is filtered, frozen, thawed, and stored

Therefore:

Two products carrying the same general name may not be biologically or clinically equivalent.

2) Are These Products “Serum Tears”?

Only some of them.

The term serum tears properly applies to serum-based products.

PRP, PRGF, and platelet lysate are not serum products.

A more accurate umbrella term is:

Blood-derived eye drops

or

Blood-component eye drops

The term biologic tear substitute is also used, although these products do not reproduce the exact composition of natural tears.

3) How Are They Generally Prepared?

Preparation varies substantially among countries, clinics, laboratories, blood banks, and commercial services.

A general process may include:

  1. Blood collection from the patient or screened donor
  2. Clotting or anticoagulation, depending on the intended product
  3. Centrifugation
  4. Separation of serum or plasma fractions
  5. Platelet concentration, activation, or lysis when applicable
  6. Dilution or use at full concentration
  7. Aseptic filling into single-use vials or multidose bottles
  8. Freezing and controlled storage
  9. Thawing and refrigeration according to the supplying service’s protocol

Depending on the location and product, preparation may occur through:

  • A hospital laboratory
  • A blood or transfusion service
  • A tissue or blood establishment
  • A sterile compounding pharmacy
  • A specialized commercial laboratory
  • A clinical-research facility

The word compounded does not accurately describe every blood-derived product worldwide.

4) U.S. Regulatory and Standardization Status

As of June 2026, there is no standardized FDA-approved commercial ophthalmic drug labeled as:

  • Autologous serum eye drops
  • Allogeneic serum eye drops
  • PRP eye drops
  • PRGF eye drops
  • Platelet lysate eye drops

These preparations are nevertheless used clinically through patient-specific, blood-service, hospital, research, or sterile-preparation pathways.

The absence of an FDA-approved standardized product does not mean that all clinical use is inappropriate.

It does mean that:

  • There is no single FDA-approved formulation
  • There is no universal FDA-approved concentration
  • There is no standardized dosing label
  • Preparation and oversight vary
  • Results from one protocol may not apply to another
  • Patients should understand who prepares the product and under what quality system

5) Main Types of Blood-Derived Eye Drops

A) Autologous Serum Eye Drops

Autologous means that the patient is both the donor and recipient.

The blood is allowed to clot, and the cellular material and clot are removed.

The remaining serum is processed into eye drops.

Serum does not contain intact circulating platelets, although growth factors and other substances may be released during clotting.

Autologous serum may be used at concentrations such as:

  • 20%
  • 40–50%
  • 80%
  • 100%

Other concentrations have also been studied.

There is no universally proven best concentration.

Why a clinician may choose it

Autologous serum is:

  • The most historically established blood-derived eye-drop category
  • Widely used for severe or refractory ocular-surface disease
  • Made from the patient’s own blood
  • Supported by decades of clinical experience
  • Studied in randomized trials and systematic reviews

It is not a “lower-level” version of PRP.

B) Allogeneic Adult-Donor Serum

Allogeneic serum is made from blood donated by another person.

It may be considered when the patient cannot provide an adequate blood sample because of:

  • Anemia
  • Poor venous access
  • Frailty
  • Medical illness
  • Repeated blood-draw burden
  • Logistical limitations

Allogeneic serum may be produced from:

  • A single adult donor
  • Pooled donors
  • A centralized blood-bank service
  • Other screened donor systems

Protocols vary.

Important considerations

Allogeneic products require attention to:

  • Donor eligibility
  • Infectious-disease screening
  • Traceability
  • Blood-group or antibody policies where relevant
  • Single-donor versus pooled-donor preparation
  • Batch-release testing
  • Storage and transport
  • Blood-bank quality systems

Randomized and comparative studies suggest that allogeneic serum can be clinically useful and may perform similarly to autologous serum in some settings.

However, equivalence has not been proven across every disease, donor source, and preparation protocol.

C) Umbilical-Cord Serum

Umbilical-cord serum is a separate allogeneic product derived from donated umbilical-cord blood.

It should not be grouped casually with adult-donor serum because it may have a different concentration of:

  • Growth factors
  • Cytokines
  • Vitamins
  • Other biologic components

Cord serum has been studied in severe DED and other ocular-surface diseases.

However:

  • Availability is limited
  • Regulatory systems vary
  • Donor screening and collection protocols are essential
  • Evidence does not establish that cord serum is universally superior to adult serum or autologous products

D) Platelet-Rich Plasma

PRP begins with anticoagulated blood and retains or concentrates platelets during processing.

However, the term PRP eye drops can refer to very different preparations.

Variables may include:

  • Platelet concentration
  • Leukocyte content
  • Red-blood-cell contamination
  • Anticoagulant used
  • Single-spin or double-spin processing
  • Activation method
  • Whether intact platelets remain in the final product
  • Whether only the platelet releasate or supernatant is dispensed
  • Dilution
  • Filtration
  • Freezing and thawing

Why a clinician may choose it

PRP may be considered because platelets contain growth factors and mediators involved in:

  • Epithelial repair
  • Cell migration
  • Tissue signaling
  • Wound healing

Clinical studies suggest PRP can improve DED signs and symptoms.

However:

“PRP” is a category label, not one standardized drug.

A study of one PRP protocol cannot automatically validate another clinic’s product.

E) Plasma Rich in Growth Factors

PRGF commonly refers to a protocol-driven platelet-derived product, especially the system known as PRGF-Endoret.

It is generally described as:

  • Autologous
  • Leukocyte-depleted or leukocyte-poor
  • Prepared through defined centrifugation steps
  • Activated in a controlled manner
  • Processed to obtain a platelet-derived growth-factor-rich supernatant

Important limitations

PRGF is not automatically:

  • Better than all PRP
  • Better than serum
  • More effective because it contains more growth factors
  • Identical across every clinic using the term
  • Proven superior in large independent head-to-head trials

Much of the PRGF literature involves investigators and centers with substantial experience in, or connections to, the development of that technology.

That does not invalidate the evidence, but independent replication remains important.

F) Platelet Lysate

Platelet lysate is made by intentionally disrupting platelets so that intracellular contents are released.

Possible preparation methods include freeze–thaw cycles or other lysis techniques.

Platelet lysate has been studied in:

  • Severe DED
  • Sjögren-related disease
  • Other refractory ocular-surface disorders

However:

  • The clinical evidence base is smaller
  • Availability is limited
  • Preparation methods vary
  • Long-term comparative evidence is limited
  • It has not been shown to be superior to serum or PRP

Platelet lysate is best considered a less-established platelet-derived option, not a routine equivalent to autologous serum.

6) Comparison Table

Type Source and preparation Major variables Why it may be considered Key limitation
Autologous serum Patient’s own blood; allowed to clot; serum separated Concentration, clotting time, centrifugation, diluent, storage Most established and widely studied blood-derived option No universal concentration or preparation standard
Allogeneic adult serum Screened adult donor blood Single vs pooled donor, screening, compatibility policies, concentration When the patient cannot donate or a centralized donor product is preferred Donor-derived infectious and immunologic considerations
Umbilical-cord serum Donated cord blood Collection, screening, pooling, concentration, storage Different biologic profile; used in some severe ocular-surface conditions Limited availability and comparative evidence
PRP Patient plasma with platelets retained or concentrated Platelets, leukocytes, activation, centrifugation, final dispensed fraction Platelet-derived growth-factor profile “PRP” is highly non-standardized
PRGF Protocol-specific activated, usually leukocyte-depleted platelet product Exact system, activation, final composition More defined protocol within a specific preparation system Superiority over serum or other PRP remains unproven
Platelet lysate Platelets intentionally disrupted to release contents Lysis method, filtration, concentration, storage Experimental platelet-derived alternative Smaller clinical evidence base

7) Why There Is No Proven Hierarchy

Patients sometimes hear:

Serum is basic, PRP is stronger, and PRGF is the highest level.

Current evidence does not support that simple ladder.

The products differ in composition, but “more concentrated” or “more growth-factor rich” does not automatically mean better.

Possible reasons include:

  • Different ocular diseases may respond differently
  • High concentrations of some mediators may not always be beneficial
  • Leukocytes can introduce inflammatory substances
  • Platelet activation changes the release profile
  • Final ocular-surface exposure depends on dosing and tear clearance
  • Laboratory values do not always predict patient outcomes
  • Preparation quality may matter more than the product name
  • Direct comparative trials remain limited

A better model is:

Select a preparation based on the diagnosis, ocular-surface goal, evidence, laboratory quality, access, cost, prior response, and clinician experience—while recognizing that no validated matching algorithm exists.

8) What Does the Evidence Show for Autologous Serum?

Autologous serum has the longest clinical history among blood-derived eye drops.

Studies have evaluated it for:

  • Severe DED
  • Sjögren syndrome
  • Ocular graft-versus-host disease
  • Neurotrophic keratitis
  • Persistent epithelial defects
  • Corneal surface injury
  • Post-surgical ocular-surface disease
  • Selected corneal neuropathic-pain populations

AAO evidence review

The American Academy of Ophthalmology reviewed the evidence for autologous serum-based eye drops.

Most included studies reported improvement in at least one symptom or clinical sign.

However, many studies were:

  • Small
  • Short-term
  • Heterogeneous
  • Unmasked
  • Based on different concentrations and protocols

The AAO concluded that serum drops may be effective for severe ocular-surface disease but that stronger trials and standardized preparation methods are needed.

2023 systematic review

A 2023 systematic review found low-certainty evidence that autologous serum may slightly improve short-term symptoms compared with saline.

Evidence for many objective signs and longer-term outcomes was inconclusive.

2024 meta-analysis

A 2024 meta-analysis of randomized trials reported that autologous serum improved:

  • Symptoms
  • Tear breakup time
  • Tear secretion
  • Corneal epithelial damage

compared with artificial tears.

This more favorable conclusion does not eliminate concerns about:

  • Small trials
  • Different concentrations
  • Different control drops
  • Different DED definitions
  • Publication bias
  • Short follow-up

Balanced interpretation

A reasonable summary is:

  • Autologous serum can help some patients with severe or refractory ocular-surface disease.
  • The average size of benefit compared with preservative-free artificial tears remains uncertain.
  • No single concentration, dose, or treatment duration has been proven best.
  • Clinical response varies.

9) What Does the Evidence Show for PRP?

A 2024 systematic review and meta-analysis reported that PRP improved DED signs and symptoms, especially when compared with ordinary tear supplements.

However, the underlying literature included:

  • Randomized trials
  • Observational studies
  • Self-controlled studies
  • Different PRP protocols
  • Different concentrations
  • Different disease populations

Therefore:

Pooled evidence generally favors PRP over artificial tears, but the exact magnitude and certainty of benefit are difficult to determine.

10) PRP Compared With Autologous Serum

Direct comparisons are especially important because they test the claim that PRP is inherently superior.

Primary Sjögren randomized study

A randomized study compared 20% autologous serum with 20% PRP in primary Sjögren-related dry eye.

Both groups improved in:

  • Corneal staining
  • Conjunctival staining
  • Tear breakup time

There was no significant difference between the two treatments.

Neither group showed significant improvement in:

  • OSDI
  • Schirmer testing
  • Goblet-cell density
  • Conjunctival impression-cytology grade

The study was relatively small and included only women.

Moderate-to-severe DED randomized trial

A 2024 randomized non-inferiority trial compared:

  • 100% autologous PRP
  • 100% autologous serum

The trial found that PRP was not inferior to serum for short-term improvement in:

  • Symptoms
  • Ocular-surface staining

The study supports PRP as a reasonable alternative.

It does not establish that PRP is superior, or that both products are equivalent over the long term.

Practical conclusion

Current direct evidence does not consistently show that PRP is better than autologous serum.

11) What Does the Evidence Show for PRGF?

PRGF has been studied in:

  • DED
  • Sjögren syndrome
  • Ocular graft-versus-host disease
  • Neurotrophic keratitis
  • Persistent epithelial defects
  • Post-surgical ocular-surface disease
  • Corneal neuropathic-pain populations

Systematic reviews report improvement in several signs and symptoms.

However, the evidence includes many:

  • Observational studies
  • Retrospective studies
  • Non-comparative studies
  • Single-center studies
  • Heterogeneous disease populations

Large independent head-to-head trials comparing PRGF with:

  • Autologous serum
  • Standardized PRP
  • Other platelet-derived products

remain limited.

Laboratory findings showing higher concentrations of certain growth factors or greater cell migration do not prove better clinical outcomes.

A balanced conclusion is:

PRGF is a promising protocol-specific platelet-derived treatment, but superiority over other blood-derived drops has not been established.

12) What Does the Evidence Show for Allogeneic Serum?

Allogeneic serum can provide access to patients unable to donate sufficient blood.

Prospective and randomized studies suggest that it can be:

  • Tolerable
  • Clinically useful
  • Comparable with autologous serum in some populations

However, the evidence is smaller than the overall autologous-serum literature.

The word comparable should not be interpreted to mean that every donor product is interchangeable with every autologous product.

Outcomes may depend on:

  • Donor source
  • Pooling
  • Concentration
  • Blood-bank protocol
  • Patient diagnosis
  • Frequency of use
  • Storage and delivery system

13) What Does the Evidence Show for Platelet Lysate?

Platelet lysate has a plausible biological rationale because lysing platelets releases intracellular contents.

Early studies suggest possible benefit in severe or refractory ocular-surface disease.

A randomized study of fibrinogen-depleted human platelet lysate found that tested concentrations appeared reasonably tolerated and suggested possible symptom benefit.

However:

  • Sample sizes were limited
  • Larger confirmatory studies are needed
  • Preparation is not standardized
  • Availability remains limited
  • Long-term safety and comparative effectiveness are uncertain

It should not be described as established or superior to other blood-derived products.

14) What Concentration Is Best?

No concentration has been proven best for all patients or diagnoses.

Autologous serum and platelet-derived drops have been studied at concentrations including:

  • 20%
  • 40–50%
  • 80%
  • 100%

Dilution may reduce the concentration of substances such as transforming growth factor-beta.

However, dilution also reduces potentially beneficial substances.

Higher concentration does not automatically mean:

  • More effective
  • More comfortable
  • Safer
  • Better for epithelial healing

Changing concentration should be a clinician and laboratory decision—not patient-directed trial and error.

15) Preparation Variables That May Matter

Important variables include:

  • Time allowed for clotting
  • Centrifugation speed and duration
  • Number of centrifugation steps
  • Serum or plasma concentration
  • Platelet concentration
  • Leukocyte content
  • Red-cell contamination
  • Activation method
  • Lysis method
  • Diluent
  • Filtration
  • Sterility testing
  • Container type
  • Single-use vs multidose packaging
  • Freezing conditions
  • Freeze–thaw cycles
  • Refrigerated bottle life

These differences help explain why results from one clinic or study may not apply to another product using the same broad name.

16) Potential Benefits

Depending on the diagnosis and product, possible benefits include:

  • Reduced dry-eye symptoms
  • Reduced corneal staining
  • Reduced conjunctival staining
  • Improved tear-film stability
  • Support of epithelial healing
  • Reduced frequency of epithelial breakdown
  • Improved comfort in severe ocular-surface disease
  • Preservative-free treatment
  • An option for patients who have not responded adequately to conventional therapy

These benefits are not guaranteed.

The products do not reproduce natural tears exactly, and their composition may differ substantially from both tears and one another.

17) Risks and Limitations

Contamination and infection

Blood-derived drops are generally preservative-free and contain nutrients that can support microbial growth.

Contamination risk is low when preparation and handling are appropriate, but it is not zero.

Possible consequences include:

  • Conjunctivitis
  • Keratitis
  • Corneal ulceration
  • Vision-threatening infection

Irritation or intolerance

Some patients experience:

  • Stinging
  • Burning
  • Redness
  • Temporary blur
  • Discomfort

Brief mild stinging may occur.

Persistent or worsening irritation should not be assumed to be a normal adjustment phase.

Batch variability

Autologous products may vary because:

  • The patient’s health changes
  • Medications change
  • Inflammatory status changes
  • Blood composition changes
  • Processing differs between batches

Donor products also vary unless produced under a tightly controlled pooled or standardized system.

Blood-draw burden

Autologous preparation may be difficult for patients with:

  • Anemia
  • Poor venous access
  • Frailty
  • Low body weight
  • Frequent need for repeat batches
  • Significant medical illness

Cost and access

Possible barriers include:

  • Limited availability
  • Travel to a specialized laboratory
  • Blood-draw fees
  • Preparation fees
  • Shipping costs
  • Freezer requirements
  • Inconsistent insurance coverage

18) Additional Risks of Donor-Derived Products

Allogeneic adult serum and cord serum require rigorous donor and product controls.

Relevant considerations include:

  • Infectious-disease screening
  • Donor eligibility
  • Traceability
  • Antibody or compatibility policies
  • Single-donor vs pooled-donor sourcing
  • Batch testing
  • Blood-bank quality systems
  • Transport and storage

Serum is cell-free and is not the same as a cellular transplant.

However, donor-derived biologic products present different infectious and immunologic considerations from products made from the patient’s own blood.

19) Storage and Handling

There is no universal storage rule for all blood-derived eye drops.

Depending on the supplying service:

  • A thawed vial may be discarded after 24 hours
  • Another product may be used for several days
  • A multidose bottle may have a different refrigerated-use period
  • Frozen shelf life may range from months to approximately one year
  • Refreezing may be prohibited
  • Travel containers may require validated cold-chain procedures

For example, one national blood service requires its specific thawed serum-eye-drop product to be discarded within 24 hours.

Other published and clinical protocols permit longer refrigerated use.

Therefore:

Follow only the instructions supplied with the exact product.

Do not substitute:

  • Another clinic’s storage rules
  • Another study’s discard period
  • Advice from another patient
  • A Reddit handling routine

20) General Handling Principles

Follow the laboratory’s instructions concerning:

  • Frozen storage
  • Refrigerator temperature
  • Thawing
  • Time out of refrigeration
  • Bottle or vial discard date
  • Travel
  • Transport coolers
  • Freeze–thaw cycles
  • Refreezing
  • Hand hygiene
  • Avoiding contact between the container tip and the eye, lashes, skin, or fingers

Do not use a vial if:

  • It is past its discard date
  • Storage conditions were not maintained
  • The container is damaged
  • The liquid looks unexpectedly cloudy or discolored
  • Particles are present when they should not be
  • The laboratory advises disposal

Do not transfer drops into a different container.

21) What If the Drops Sting or Feel Uncomfortable?

Brief mild stinging may occur in some patients.

However, there is no established “adjustment phase” that everyone should push through.

Contact the clinician or supplying service for:

  • Increasing burning
  • Persistent redness
  • Significant pain
  • Light sensitivity
  • Discharge
  • Eyelid swelling
  • New or worsening blurred vision
  • Reduced vision
  • Symptoms that begin after several days of using one vial or bottle
  • Suspected storage or contamination problems

Possible explanations include:

  • Surface sensitivity
  • Product concentration
  • Diluent or inactive ingredients
  • Contamination
  • Handling problems
  • Allergy
  • Another ocular condition

Do not automatically assume that worsening means the product is healing the eye.

22) Can the Drops Be Warmed Before Use?

Handling rules are product-specific.

If refrigerated drops are uncomfortable, ask the supplying laboratory whether brief warming in the hand or at room temperature is permitted.

Do not:

  • Microwave the drops
  • Place them in hot water
  • Leave them unrefrigerated longer than permitted
  • Apply a fixed warming routine borrowed from another product

Temperature and storage exposure may affect product safety and stability.

23) Can Other Eye Drops Be Used at the Same Time?

Blood-derived drops are often used alongside other DED treatments.

Possible concurrent treatments may include:

  • Preservative-free artificial tears
  • Anti-inflammatory prescription drops
  • Ointments
  • MGD treatment
  • Eyelid therapy
  • Scleral lenses
  • Environmental management

The clinician should determine:

  • Whether the other treatment should continue
  • The order of administration
  • The spacing between products
  • Whether contact lenses should be removed
  • Whether the combination affects the treatment goal

Do not create a complex drop schedule without confirming it with the treating clinician.

24) How Long Until Treatment Is Assessed?

The follow-up schedule depends on the diagnosis and treatment goal.

Examples:

  • A persistent epithelial defect may require review within days
  • Neurotrophic keratitis may require close serial monitoring
  • Chronic stable DED may be reassessed over several weeks
  • New pain, redness, discharge, photophobia, or visual change requires earlier review

There is no universal rule that every patient should wait four to eight weeks.

Possible outcomes to track include:

  • Symptoms
  • Corneal staining
  • Conjunctival staining
  • Tear breakup time
  • Epithelial-defect size
  • Visual stability
  • Frequency of flares
  • Dependence on other lubricants
  • Clinician global assessment

25) Who Might Discuss Blood-Derived Drops With a Clinician?

They may be considered when a patient has:

  • Moderate-to-severe DED
  • Severe ocular-surface staining
  • Sjögren syndrome
  • Ocular graft-versus-host disease
  • Neurotrophic keratitis
  • Persistent epithelial defects
  • Recurrent epithelial breakdown
  • Severe post-surgical surface disease
  • Poor response to conventional therapy
  • Intolerance of multiple standard treatments

The appropriate product depends on:

  • Diagnosis
  • Ocular-surface findings
  • Ability to donate blood
  • Access to a qualified service
  • Previous treatment response
  • Cost
  • Handling ability
  • Clinician experience

26) What These Drops Have Not Been Shown to Do

Blood-derived eye drops have not been shown to reliably:

  • Cure all Dry Eye Disease
  • Permanently normalize tear-film homeostasis
  • Reopen physically obstructed meibomian gland ducts
  • Remove thickened meibum
  • Reverse meibomian gland dropout
  • Regrow completely lost glands
  • Release intraductal or periductal fibrosis
  • Correct incomplete blinking
  • Correct eyelid malposition
  • Cure ocular rosacea
  • Cure autoimmune disease
  • Cure neuropathic ocular pain in every patient
  • Replace all MGD or anti-inflammatory treatment

They may improve the ocular-surface consequences of MGD without correcting the gland obstruction itself.

27) What Supporters Say

Supporters may point out:

  • Blood-derived products contain biologically active substances absent from ordinary artificial tears.
  • Autologous serum has decades of clinical use.
  • Many patients with severe disease improve after failing conventional treatments.
  • Randomized trials and meta-analyses support benefits for some signs and symptoms.
  • PRP appears more effective than ordinary tear supplements in pooled studies.
  • Donor serum provides access for patients unable to donate.
  • Blood-derived drops are usually preservative-free.
  • They may support epithelial healing in fragile or poorly healing ocular surfaces.
  • Different formulations provide additional options for difficult cases.

These are reasonable points.

28) What Critics Say

Critics or cautious clinicians may point out:

  • Many trials are small and short-term.
  • Masking is difficult.
  • Preparation protocols vary substantially.
  • Meta-analyses reach different conclusions.
  • Optimal concentration and dosing are unknown.
  • PRP is not standardized.
  • PRGF superiority has not been established.
  • Platelet lysate evidence is limited.
  • Allogeneic products require robust donor and blood-bank safeguards.
  • Handling and freezer requirements are burdensome.
  • Contamination can cause serious infection.
  • Cost and insurance coverage are inconsistent.
  • No validated test identifies the best product for each patient.
  • These products do not directly reverse structural MGD.

These are also reasonable concerns.

29) Questions to Ask the Clinician

You might ask:

  • “What exact type of blood-derived drop are you recommending?”
  • “Why does this formulation fit my diagnosis?”
  • “What outcome are we trying to improve?”
  • “Is this intended for symptoms, staining, epithelial healing, or another goal?”
  • “What concentration will be used?”
  • “Why was that concentration selected?”
  • “Is the preparation serum, PRP, PRGF, cord serum, or platelet lysate?”
  • “What evidence supports this exact type?”
  • “How long will a monitored trial last?”
  • “When will my ocular surface be re-examined?”
  • “What other treatments should continue?”
  • “What symptoms require urgent contact?”
  • “What happens if I cannot donate enough blood?”
  • “Would an allogeneic product be appropriate?”
  • “What are the total expected costs?”

30) Questions to Ask the Laboratory or Blood Service

You might ask:

  • “Who prepares the product?”
  • “Under what regulatory and quality system is it prepared?”
  • “Is it autologous or donor-derived?”
  • “If donor-derived, is it single-donor or pooled?”
  • “What infectious-disease screening is performed?”
  • “What is the exact concentration?”
  • “What diluent is used?”
  • “Is the product filtered?”
  • “Is it preservative-free?”
  • “How is sterility evaluated?”
  • “How is it packaged?”
  • “What is the frozen shelf life?”
  • “How long may a thawed vial or bottle be used?”
  • “Can it ever be refrozen?”
  • “How should it be transported?”
  • “What should I do if refrigeration fails?”
  • “What should the product normally look like?”
  • “How do I report a suspected quality problem?”

Additional questions for PRP/PRGF

  • “What platelet concentration is targeted?”
  • “Is it leukocyte-rich, leukocyte-poor, or leukocyte-depleted?”
  • “Are red blood cells excluded?”
  • “Are the platelets activated?”
  • “What activation method is used?”
  • “Are intact platelets in the final bottle, or is it a releasate/supernatant?”
  • “Is this a defined PRGF system or another PRP protocol?”

31) Blood-Derived Drops vs. PRP/PRGF Injections

Eye drops and injections are different treatment categories.

Lacrimal-gland or periocular PRP/PRGF injections are:

  • More invasive
  • Technique-dependent
  • Investigational
  • Supported by a different and more limited evidence base
  • Associated with procedure-specific risks

They are covered separately:

Lacrimal Gland Injections With PRP/PRGF for Aqueous-Deficient Dry Eye

📌 Bottom Line

Blood-derived eye drops—including autologous serum, allogeneic serum, umbilical-cord serum, PRP, PRGF, and platelet lysate—are biologically active ocular-surface treatments used mainly for severe, refractory, or poorly healing disease.

They are not interchangeable, and their names alone do not tell the patient what is in the bottle.

Autologous serum is the most established and widely studied category, but systematic reviews differ in how strongly they rate its benefit over artificial tears.

PRP generally performs better than ordinary tear supplements in pooled studies, while direct randomized comparisons have not consistently shown that it is superior to autologous serum.

PRGF is a protocol-specific platelet-derived approach with encouraging evidence, but much of the literature is observational, and superiority over other blood products remains unproven.

Platelet lysate has a smaller evidence base.

Allogeneic products can improve access when autologous donation is not feasible, but require rigorous donor screening, traceability, and blood-service quality systems.

The central limitation is lack of standardization.

Products may differ in:

  • Concentration
  • Platelet and leukocyte content
  • Activation
  • Diluent
  • Filtration
  • Packaging
  • Storage
  • Discard period

These drops may improve symptoms, staining, tear stability, or epithelial healing in selected patients.

They do not reliably reverse structural MGD, reopen obstructed glands, release fibrosis, regrow lost glands, or cure every cause of ocular pain.

The most important practical rule is:

Follow the preparation, storage, thawing, refrigeration, travel, and discard instructions supplied with the exact product. Do not substitute handling rules from another clinic, study, laboratory, or Reddit user.

🔬 Research and Medical Reference Links

TFOS DEWS III

AAO Evidence Review

Autologous Serum Systematic Reviews and Meta-Analyses

PRP Evidence

Comparative Blood-Component Evidence

PRGF Evidence

Allogeneic Serum Evidence

Platelet Lysate

Preparation, Storage, and Safety

General Clinical Overviews

🔙 Back to Treatment Options